Jijun Dong

Company: Salubris Biotherapeutics Inc.

Job title: Chief Scientific Officer

Seminars:

Going Beyond IL-2 to Explore Different Possibilities for the Development of Cytokine-Based Drugs 9:01 am

Although the IL-2s have been the forefront of research within the field of cytokine-based drugs, many interleukins and interferons beyond IL-2 are becoming increasingly relevant. The applications of these cytokines are vast and their different mechanisms of action open up the field to more R&D and an endless number of possibilities to tackle the various…Read more

day: Pre-Conference Workshop Day